About Hemogenomics
Hemogenomics is a company based in Bengaluru (India) founded in 2002. Hemogenomics has raised $219.21 thousand across 1 funding round from investors including Synergenics. The company has 99 employees as of April 09, 2024. Hemogenomics offers products and services including ID-NAT and Cancer Screening. Hemogenomics operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.
- Headquarter Bengaluru, India
- Employees 99 as on 09 Apr, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hemogenomics Private Limited
- Date of Incorporation 22 Jan, 2002
- Jurisdiction Bangalore., Karnataka, India
-
Annual Revenue
$12.37 M (USD)44.71as on Mar 31, 2023
-
Net Profit
$658.37 K (USD)131.56as on Mar 31, 2023
-
EBITDA
$1 M (USD)169.06as on Mar 31, 2023
-
Total Equity Funding
$219.21 K (USD)
in 1 rounds
-
Latest Funding Round
$219.21 K (USD), Seed
Aug 12, 2008
- Investors
-
Employee Count
99
as on Apr 09, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemogenomics
Hemogenomics offers a comprehensive portfolio of products and services, including ID-NAT and Cancer Screening.
Technology for detecting HIV and Hepatitis in donated blood.
Services for early detection of cervical cancer.
Funding Insights of Hemogenomics
Hemogenomics has successfully raised a total of $219.21K through 1 strategic funding round. The most recent funding activity was a Seed round of $219.21 thousand completed in August 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hemogenomics
Hemogenomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Synergenics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A consortium of biotech companies is operated by Synergenics.
|
Locked | Locked | Locked |
Investor details for Hemogenomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemogenomics
Investment portfolio details for Hemogenomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hemogenomics
Detailed financials for Hemogenomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemogenomics Comparisons
Peer comparison for Hemogenomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemogenomics
Hemogenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Hemogenomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemogenomics
Complete news archive for Hemogenomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemogenomics
Hemogenomics was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Hemogenomics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Hemogenomics is a funded company, having raised a total of $219.21K across 1 funding round to date.
As of Apr 09, 2024, the latest employee count at Hemogenomics is 99.
Annual revenue of Hemogenomics is $12.37M as on Mar 31, 2023.
Hemogenomics was established in 2002 in Bengaluru, India, within the biotechnology sector. Technology focused on screening blood donations for early disease detection is offered, aiming to prevent the transmission of HIV and hepatitis. The ID-NAT method is employed, where antibodies in individual samples are tested to identify infections. Operations center on nucleic acid amplification for reliable results in blood safety protocols.
Hemogenomics's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Hemogenomics offers ID-NAT and Cancer Screening.
Hemogenomics has 1 investor. Key investors include Synergenics.
The valuation of Hemogenomics is $502.85K as of Aug 2008.